bioRxivGenomicsPreprint
Single-cell RNA-seq analysis of human coronary arteries using an enhanced workflow reveals SMC transitions and candidate drug targets
Wei FengiD, Chani J. HodonskyiD, Adam W. TurneriD, Doris WongiD, Yipei SongiD, Nelson B. BarrientosiD, José Verdezoto MosqueraiD, Clint L. MilleriD
Abstract
Background and AimsThe atherosclerotic plaque microenvironment is highly complex, and selective agents that modulate plaque stability or other plaque phenotypes are not yet available. We sought to investigate the human atherosclerotic cellular environment using scRNA-seq to uncover potential therapeutic approaches. We aimed to make our workflow user-friendly, reproducible, and applicable to other disease-specific scRNA-seq datasets. MethodsHere we incorporate automated cell labeling, pseudotemporal ordering, ligand-receptor evaluation, and drug-gene interaction analysis into an enhanced and reproducible scRNA-seq analysis workflow. Notably, we also developed an R Shiny based interactive web application to enable further exploration and analysis of the scRNA dataset. ResultsWe applied this analysis workflow to a human coronary artery scRNA dataset and revealed distinct derivations of chondrocyte-like and fibroblast-like cells from smooth muscle cells (SMCs), and show the key changes in gene expression along their de-differentiation path. We highlighted several key ligand-receptor interactions within the atherosclerotic environment through functional expression profiling and revealed several attractive avenues for future pharmacological repurposing in precision medicine. Further, our interactive web application, PlaqView (www.plaqview.com), allows other researchers to easily explore this dataset and benchmark applicable scRNA-seq analysis tools without prior coding knowledge. ConclusionsThese results suggest novel effects of chemotherapeutics on the atherosclerotic cellular environment and provide future avenues of studies in precision medicine. This publicly available workflow will also allow for more systematic and user-friendly analysis of scRNA datasets in other disease and developmental systems. PlaqView allows for rapid visualization and analysis of atherosclerosis scRNA-seq datasets without the need of prior coding experience. Future releases of PlaqView will feature additional larger scRNA-seq and scATAC-seq atherosclerosis-related datasets, thus providing a critical resource for the field by promoting data harmonization and biological interpretation.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: database / resource
- approach: statistical model
- approach: experimental assay
- Citations
- 9
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis
José Verdezoto Mosquera, Gaelle E Auguste, … Clint L. Miller·Cell ReportsPeer-reviewed·Nov 1, 2023
- Transcriptomic, Specific Marker, and Pathway Analysis of Smooth Muscle Cell Foam Cells Relative to Macrophage Foam Cells in Human Atherosclerosis
Sima Allahverdian, Yuancheng Mao, … Gordon A. Francis·bioRxiv·Aug 1, 2026
- Integrated single-cell atlas of human atherosclerotic plaques
Korbinian Traeuble, Matthias Munz, … Matthias Heinig·Nature CommunicationsPeer-reviewed·Sep 10, 2025
- Encompassing view of spatial and single-cell RNA-seq renews the role of the microvasculature in human atherosclerosis
Tore Bleckwehl, Sidrah Maryam, … Sikander Hayat·bioRxiv·Dec 15, 2023
- Mapping atherogenesis mechanisms in smooth muscle cells by targeting genes linked to coronary artery disease
Julián Albarrán-Juárez, Anton Markov, … Jacob Fog Bentzon·iSciencePeer-reviewed·Oct 5, 2025
- Decoding the transcriptome of atherosclerotic plaque at single-cell resolution
Tom Alsaigh, Doug Evans, … Ali Torkamani·bioRxiv·Mar 3, 2020